Atopic dermatitis is a type of inflammatory skin disease, also called as eczema that disrupts the skin barrier and its ability to hold moisture. It is the most common chronic skin disease with genetic base affecting large number of population. Globally, up to 1-10% of the adult and 5-30% pediatric population have atopic dermatitis. Adults in China are highly affected, whereas infants in France and the United Kingdom have the highest rates. Adult patients can be acceptably managed with topical treatments. Infants with recalcitrant atopic dermatitis have a poorer quality of life and may need alternative treatment modalities which is expecting the vertical to emerge with a novel treatment for atopic dermatitis.
Atopic Dermatitis Drugs Market Outlook
- Development of ideal drugs and treatments is an extensive need with high safety and efficiency
- Increasing food and skin allergies raised the atopic dermatitis cases in infants is contributing the atopic dermatitis drug market growth
- Lack of good & safe therapeutics, adverse reactions, side effects and high cost of treatment hinder the atopic dermatitis drug market
Atopic Dermatitis Drugs Market COVID-19 Impact
- The global pandemic of Coronavirus (COVID-19) has triggered stock market instability, tight border controls, and worldwide lockdown, leading the healthcare industry, as well as large companies and governments, to restock supply chains
- The whole world is experiencing severe impact on social and financial sectors, and all global industries are facing challenges during the COVID-19 pandemic
- Rising support from governments and several companies can help in the fight against this highly contagious disease
- There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic
Atopic Dermatitis Drugs Segmental Highlights
- The atopic dermatitis drug market is segmented by drug type, route of administration, distribution channel and geography
- Current medical treatment available for atopic dermatitis are corticosteroids, immunosuppressant, pde-4 inhibitor, immunomodulating agents, emollients, photo therapy and directed therapy. Corticosteroids such as triamcinolone, betamethasone valerate etc., helps to reduce inflammation, itching, and thickening of the skin (lichenification)
- Atopic dermatitis drugs are formulated for administration via different route such as oral, topical and injectable. Topical route is massively used as it is convenient to use, consisting corticosteroids majorly
- Atopic dermatitis drugs are marketed through distribution channels include hospital, retail pharmacies, online pharmacies and others such as dermatology clinics, drug stores, mail order pharmacies etc.
Atopic Dermatitis Drugs Market by Geography
Atopic dermatitis drugs market is analyzed across the various regions geographically including North America, Europe, Asia Pacific and rest of world. In 2019, North America was at dominant position due to increasing number of atopic dermatitis cases and high R&D investment for the development of novel therapies. Asia pacific is expected to flare up rapidly during projection period due to increasing prevalence of atopic dermatitis, increasing variety of allergens, in the region.
Atopic Dermatitis Drugs Market Key Players
Pivotal market performers in the atopic dermatitis drugs market are Bayer Healthcare, Valent Pharmaceutical Inc., Astellas Pharma Inc., Meda AB, Novartis AG., Sanofi SA, Anacor Pharmaceutical Inc., LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Allergan Plc., Mylan and Encore dermatology. Major players operating in this market are focusing on merging, acquisitions and new product launch as novel treatment therapies for the disease, to enhance the market growth
Atopic Dermatitis Drugs Market Recent Developments
May 2019: Pfizer Inc. announced positive top-line results from a Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor in patients aged 12 and older with moderate to severe atopic dermatitis.
March2019: The U.S. Food and Drug Administration (FDA) has approved Dupixent for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
The atopic dermatitis drug market is segmented by drug type, route of administration, distribution channel and geography. Modern medical treatment available for atopic dermatitis are corticosteroids, immunosuppressant, pde-4 inhibitor, immunomodulating agents, emollients, photo therapy and directed therapy. Atopic dermatitis drugs are formulated to administer via various route such as oral, topical and injectable.
Topical route is tremendously used as it is convenient to use and contain corticosteroids majorly.Atopic dermatitis drugs are promoted through distribution channels include hospital, retail pharmacies, online pharmacies and others such as dermatology clinics, drug stores, mail order pharmacies etc.
Atopic dermatitis drugs market is studied across the various regions geographically including North America, Europe, Asia Pacific and rest of world. Followed by Asia Pacific, in 2019, North America remained the dominating region due to increasing number of atopic dermatitis cases and high R&D investment for the development of novel therapies.
Why to buy this report:
- The report offers changing market dynamics in the atopic dermatitis drugs, presenting historical, current and projected market size in terms of value (USD Million)
- The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of atopic dermatitis drugs. It presents a comprehensive assessment of geographical regions exhibiting promising growth, potential and niche segments, and a neutral perspective on the atopic dermatitis drugs market performance
- The report also offers strategic recommendations in key business segments based on the market estimations and competitive landscape, mapping the key common trends of atopic dermatitis drugs market
